SCHEMBL66337

SCHEMBL66337

Cc1cccc(CBr)c1[N+](=O)[O-]

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.64
ALDH1A1 P00352 3/20 0.64
TSHR P16473 4/20 0.56
KAT2B Q92831 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 3/20 0.43
BMP1 P13497 2/20 0.43
HSD17B10 Q99714 1/20 0.42
POLB P06746 2/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
CYP3A4 P08684 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2027979 0.86 ALDH1A1 (0.46) TDP1ALDH1A1TSHRHPGDCYP3A4
SCHEMBL13344110 0.85 TDP1 (0.69) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL16310260 0.83 TDP1 (0.45) TDP1ALDH1A1TSHRPOLBMEN1
SCHEMBL18138442 0.83 TDP1 (0.67) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL67211 0.81 TDP1 (0.64) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL66829 0.81 ALDH1A1 (0.64) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL31729335 0.81 TDP1 (0.64) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL16958303 0.80 ALDH1A1 (0.62) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL635089 0.80 ALDH1A1 (1.00) TDP1ALDH1A1TSHRKAT2BSMN1; SMN2
SCHEMBL1167739 0.79 TSHR (0.53) TDP1ALDH1A1TSHRSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3081559-B1 AROMATIC COMPOUND AND APPLICATION FOR SAME SUMITOMO CHEMICAL CO (JP) 2019-05-15 EP disclosed
US-10011615-B2 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties MERCK SHARP & DOHME CORP. (US) 2018-07-03 US disclosed
CN-105814024-B Aromatic compounds and application thereof 住友化学株式会社 2018-04-17 CN disclosed
US-9708347-B2 Heterobicyclo-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties MERCK SHARP & DOHME CORP. (US) 2017-07-18 US disclosed
US-20170197991-A1 HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2017-07-13 US disclosed
US-9573904-B2 Aromatic compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-21 US disclosed
US-20160311775-A1 AROMATIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-10-27 US disclosed
EP-3081559-A1 AROMATIC COMPOUND AND APPLICATION FOR SAME Sumitomo Chemical Company, Limited (JP) 2016-10-19 EP disclosed
CN-105814024-A Aromatic compound and application for same 住友化学株式会社 2016-07-27 CN disclosed
US-20150361098-A1 HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME CORP. (US) 2015-12-17 US disclosed
EP-1812420-A1 TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS Nicholas Piramal India Limited (IN) 2007-08-01 EP disclosed
US-7101886-B2 Phenylalkyl and pyridylalkyl piperazine derivatives WARNER LAMBERT COMPANY (US) 2006-09-05 US disclosed
WO-2006051476-A1 TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS NICHOLAS PIRAMAL INDIA LIMITED (IN) 2006-05-18 WO disclosed
EP-1562919-A1 PHENYLALKYL AND PYRIDYLALKYL PIPERAZINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-08-17 EP disclosed
US-20040186108-A1 Phenylalkyl and pyridylalkyl piperazine derivatives CHO STEPHEN SUNG YONG (US) 2004-09-23 US disclosed
WO-2004041793-A1 PHENYLALKYL AND PYRIDYLALKYL PIPERAZINE DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2004-05-21 WO disclosed
WO-1996017612-A1 USE OF SUBSTITUTED PHENYLAMIDINE AND PHENYLGUANIDINE COMPOUNDS FOR THE TREATMENT OF CEREBRAL AND CARDIAC ISCHAEMIA, CONVULSION AND SICKLE CELL ANAEMIA KNOLL AKTIENGESELLSCHAFT (DE) 1996-06-13 WO disclosed
EP-0150169-B1 A PROCESS FOR PREPARING SUBSTITUTED BENZOTRICHLORIDE COMPOUNDS Monsanto Company (US) 1987-11-11 EP disclosed
US-4593144-A REACTING SUBSTITUTED BENZAL CHLORIDES WITH PRECHLOROALKANE IN PRESENCE OF BASE AND PHASE TRANSFER CATALYST MONSANTO COMPANY (US) 1986-06-03 US disclosed
EP-0150169-A2 A process for preparing substituted benzotrichloride compounds Monsanto Company (US) 1985-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186108-A1 Phenylalkyl and pyridylalkyl piperazine derivatives CNR1, CNR2, PMP22 TDP1 1289/4885ALDH1A1 222/4885TSHR 959/4885
US-20150361098-A1 HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA3, ADORA1 TDP1 842/4885ALDH1A1 1123/4885TSHR 267/4885
US-20170197991-A1 HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES ADORA2A, ADORA3, ADORA1 TDP1 920/4885ALDH1A1 858/4885TSHR 304/4885
US-20160311775-A1 AROMATIC COMPOUND AND USE THEREOF ZCCHC8, CBR3, CBX8 TDP1 4160/4885ALDH1A1 3176/4885TSHR 458/4885
US-10011615-B2 Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties ADORA2A, ADORA3, ADORA1 TDP1 980/4885ALDH1A1 956/4885TSHR 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.